Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet β-cells

British Journal of Pharmacology

Volumn 126, Issue 5, 1999, Pages 1205-1213

  Yada, Toshihiko ^a,b   Nakata, Masanori ^a   Shiraishi, Tomoko ^a   Kakei, Masafumi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

Author keywords

Cytosolic Ca2+; Diabetes; HMG CoA reductase inhibitor; Insulin secretion; Islet; L type Ca2+ channel; Lipophilicity; Pravastatin; Simvastatin; cell

Indexed keywords

ARGININE; CALCIUM CHANNEL; CALCIUM ION; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; POTASSIUM CHLORIDE; PRAVASTATIN; SIMVASTATIN;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; INSULIN RELEASE; LIPOPHILICITY; NONHUMAN; PANCREAS ISLET BETA CELL; PATCH CLAMP; PATHOGENESIS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

EID: 0032978644     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0702397     Document Type: Article

References (51)

1. ALBERTS, A.W. (1988). Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol., 62, 10J-15J.
2. AMMALA, C., ELIASSON, L., BOKVIST, K., LARSSON, O., ASHCROFT, F.M. & RORSMAN, P. (1993). Exocytosis elicited by action potentials and voltage-clamp calcium currents in individual mouse pancreatic B-cells. J. Physiol., 472, 665-688.
3. APPEL, S., RUFENACHT, T., KALAFSKY, G., TETZLOFF, W., KALLAY, Z., HITZENBERGER, G. & KUTZ, K. (1995). Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am. J. Cardiol., 76, 29A-32A.
4. ASHCROFT, F.M. & RORSMAN, P. (1989). Electrophysiology of the pancreatic β-cell. Prog. Biophys. Mol. Biol., 54, 87-143.
5. 2+ in pancreatic islets correspond to pulsatile insulin release. Am. J. Physiol., 268, E282-E287.
6. BLACHIER, F., MOURTADA, A., SENER, A & MALAISSE, W.J. (1989). Stimulus-secretion coupling of arginine-induced insulin release. Uptake of metabolized and nonmetabolized cationic amino acids by pancreatic islets. Endocrinology, 124, 134-141.
7. BYINGTON, R.P., JUKEMA, J.W., SALONEN, J.T., PITT, B., BRUSCNKE, A.V., HOEN, H., FURBERG, C.D. & MANCINI, G.B. (1995). Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation, 92, 2419-2425.
8. DOLMETSCH, R.E., XU, K. & LEWIS, R.S. (1998). Calcium oscillations increase the efficiency and specificity of gene expression. Nature, 392, 933-936.
9. 2+ in pancreatic β-cells under metabolic inhibition. Br. J. Pharmacol., 120, 1191-1198.
10. 2+ as evidenced in single pancreatic islets. J. Biol. Chem., 268, 22265-22268.
11. HAMILL, O.P., MARTY, A., NEHER, E., SAKMANN, B. & SIGWORTH, F.J. (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch., 391, 85-100.
12. 2+ oscillations in pancreatic β-cells. Biochim. Biophys. Acta, 1113, 295-305.
13. HENQUIN, J.C. (1994). Cell biology of insulin secretion. In Joslin's Diabetes Mellitus. Kahn, C.R. & Weir, G.C., eds. Philadelphia: Lea & Febigar, pp. 56-80.
14. + fluxes in pancreatic β-cells. Am. J. Physiol., 240, E245-E252.
15. HOEG, J.M. (1990). The HMG CoA reductase inhibitors. Curr. Opin. Lipidol., 1, 29-33.
16. HURMINGHAKE, D.B. (1992). HMG CoA reductase inhibitors. Curr. Opin. Lipidol., 3, 22-28.
17. ICHIHARA, K., SATOH, K. & ABIKO, Y. (1993). Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J. Cardiovasc. Pharmacol., 22, 852-856.
18. 2+ in aequorin-expressin INS-1 cells. J. Clin. Invest., 98, 2524-2538.
19. KOGA, T., KAWABATA, K., ARAI, K., MATSUSHIMA, N., KOIKE, H., KOMAI, T., TEI, M. & NAKAMURA, H. (1995). Comparative pharmacokinetics and pharmacodynamics of pravastatin and simvastatin. Bull. Mol. Biol. Med., 20, 103-105.
20. KOSAKA, K., HAGURA, R. & KUZUYA, T. (1997). Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes, 26, 944-952.
21. 2+ spike frequency can optimize gene expression. Nature, 392, 936-941.
22. MATTHEWS, D.R., NAYLOR, B.A., JONES, R.G., WARD, G.M. & TURNER, R.C. (1983). Pulsatile insulin has greater hypoglycemic effect than continuous delivery. Diabetes, 32, 617-621.
23. MCGUIRE, T.F., XU, X.-Q., COREY, S.J., ROMERO, G.G. & SEBTI, S.M. (1994). Lovastatin disrupts early events in insulin signaling: a potential mechanism of lovastatin's anti-mitogenic activity. Biochem. Biophys. Res. Commun., 204, 399-406.
24. NAKAHARA, K., KURIYAMA, M., YOSHIDOME, H., NAGATA, K., NAGADO, T., NAKAGAWA, M., ARIMURA, K., HIGUCHI, I. & OSAME, M. (1992). Experimental simvastatin-induced myopathy in rabbits. J. Neurol Sci., 113, 114-117.
25. 2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem. Biophys. Res. Commun., 202, 1579-1585.
26. 2+ oscillations in the pancreatic beta-cell line, MIN6. Diabetologia, 41, 279-286.
27. NEGRE-ARNINOU, P., VAN-VLIET, A.K., VAN-ERIC, M., VANTHIEL, G.C., VAN-LEEUWEN, R.E. & COHEN, L.H. (1997). Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim. Biophys. Acta, 1345, 259-268.
28. NEUVONEN, P.J., KANTOLA, T. & KIVISTO, K.T. (1998). Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther., 63, 332-341.
29. NIELSEN, S., SCHMITZ, O., MOLLER, N., PORKSEN, N., KLAUSEN, I.C., ALBERTI, K.G. & MOGENSEN, C.E. (1993). Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia, 36, 1079-1086.
30. OHRVALL, M.L., LITHELL, H., JOHANSSON, J. & VESSBY, B. (1995). A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism, 44, 212-217.
31. O'MEARA, N.M. & POLONSKY, K.S. (1994). Insulin secretion in vivo. In Joslin's Diabetes Mellitus. Kahn, C.R. & Weir, G.C., eds. Philadelphia: Lea & Febigar, pp. 81-96.
32. O'RAHILLY, S., TURNER, R.C. & MATTHEWS, D.R. (1988). Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N. Engl. J. Med., 318, 1225-1230.
33. PERLEY, M.J. & KIPNIS, D.M. (1967). Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest., 46, 1954-1962.
34. PFEIFER, M.A., HALTER, J.B. & PORTE JR, D. (1981). Insulin secretion in diabetes mellitus. Am. J. Med., 70, 579-588.
35. PORTE JR, D. & KAHN, S.E. (1995). The key role of islet dysfunction in type II diabetes mellitus. Clin. Invest. Med., 18, 247-254.
36. SACKS, F.M., PFEIFER, M.A., MOYE, L.A., ROULEAU, J.L., RUTHERFORD, J.D., COLE, T.G., BROWN, L., WARNICA, J.W., ARNOLD, J.M., WUN, C.C., DAVIS, B.R. & BRAUNWALD, E. (1996). The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med., 335, 1001-1009.
37. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
38. SERAJUDDIN, A.T., RANADIVE, S.A., & MAHONEY, E.M. (1991). Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci., 80, 830-834.
39. SHEPHERD, J., COBBE, SM., FORD, I., ISLES, C.G., LORIMER, A.R., MACFARLANE, P.W., MCKILLOP, J.H. & PACKARD, C.J. (1995). Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 333, 1301-1307.
40. SHEU, W.H., SHIEH, S.M., SHEN, D.D., FUH, M.M., JENG, C.Y., CHEN, Y.D. & REAVEN, G.M. (1994). Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. Am. Heart J., 127, 331-336.
41. SMITH, P.A., SAKURA, H., COLES, B., GUMMERSON, N., PROKS, P. & ASHCROFT, F.M. (1997). Electrogenic arginine transport mediates stimulus-secretion coupling in mouse pancreatic β-cells. J. Physiol., 499, 625-635.
42. TOBERT, J.A. (1988). Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol., 62, 28J-34J.
43. TOBERT, J.A. (1995). HMG-CoA reductase inhibitors, gemfibrozil, and myopathy. Am. J. Cardiol., 75, 862.
44. WOLLHEIM, C.B. & SHARP, G.W.G (1981). Regulation of insulin release by calcium. Physical. Rev., 61, 914-973.
45. XU, X.Q., MCGUIRE, T.F., BLASKOVICH, M.A., SEBTI, S.M. & ROMERO, G. (1996). Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts. Arch. Biochem. Biophys., 326, 233-237.
46. YADA, T. (1994). Action mechanisms of amino acids in pancreatic B-cells. In Insulin Secretion and Pancreatic B-cell Research. Flatt, P.R. & Lenzen, S., eds. London: Smith-Gordon and Company Limited, pp. 129-135.
47. 2+ origin. J. Physiol., 488, 13-24.
48. 2+ in response to glucose. Cell Calcium, 13, 69-76.
49. YADA, T., SAKURADA, M., IHIDA, K., NAKATA, M., MURATA, F., ARIMURA, A. & KIKUCHI, M. (1994). Pituitary adenylate cyclase activating polypeptide is an extraordinarily potent intrapancreatic regulator of insulin secretion from islet β-cells. J. Biol. Chem., 269, 1290-1293.
50. YADA, T., SAKURADA, M., ISHIHARA, H., NAKATA, M., SHIODA, S., YAEKURA, K., HAMAKAWA, N., YANAGIDA, K., KIKUCHI, M. & OKA, Y. (1997). Pituitary adenylate cyclase-activating polypeptide (PACAP) is an islet substance serving as an intra-islet amplifier of glucose-induced insulin secretion in rats. J. Physiol., 505, 319-328.
51. 2+ in rat pancreatic β-cells. Diabetes, 45, 295-301.